EMA Highlights Trial Innovation, Real-World Data Advances in Mid-Point RSS Report

The European Medicines Agency (EMA) reported “remarkable” progress despite the pandemic in a mid-point assessment of its “Regulatory Science Strategy to 2025” to build a more adaptive regulatory system that will encourage innovation — including advances in clinical trials and a new real-world data (RWD) network.
Source: Drug Industry Daily